These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The temporal sequence of G-protein expression in intimal hyperplasia. Davies MG; Barber L; Dhanraj DN; Gettys TW; Ramkumar V; Hagen PO J Surg Res; 1996 Jun; 63(1):115-22. PubMed ID: 8661183 [TBL] [Abstract][Full Text] [Related]
4. Control of the structural and functional consequences of vein graft intimal hyperplasia with a 21-aminosteroid--U74389G. Davies MG; Barber L; Dalen H; Svendsen E; Hagen PO Eur J Vasc Surg; 1994 Jul; 8(4):448-56. PubMed ID: 8088396 [TBL] [Abstract][Full Text] [Related]
5. Reduction of experimental vein graft intimal hyperplasia and preservation of nitric oxide-mediated relaxation by the nitric oxide precursor L-arginine. Davies MG; Kim JH; Dalen H; Makhoul RG; Svendsen E; Hagen PO Surgery; 1994 Sep; 116(3):557-68. PubMed ID: 8079186 [TBL] [Abstract][Full Text] [Related]
6. Control of accelerated vein graft atheroma with the nitric oxide precursor: L-arginine. Davies MG; Dalen H; Kim JH; Barber L; Svendsen E; Hagen PO J Surg Res; 1995 Jul; 59(1):35-42. PubMed ID: 7630134 [TBL] [Abstract][Full Text] [Related]
7. Local inhibition of tyrosine kinase activity markedly attenuates the development of intimal hyperplasia in experimental vein grafts. Huynh TT; Davies MG; Barber L; Svendsen E; Hagen PO J Surg Res; 1998 Jul; 77(2):104-11. PubMed ID: 9733595 [TBL] [Abstract][Full Text] [Related]
8. Characterisation of angiotensin II receptor mediated responses and inhibition of intimal hyperplasia in experimental vein grafts by the specific angiotensin II receptor inhibitor, L158,809. Davies MG; Fulton GJ; Barber L; Dalen H; Svendsen E; Hagen PO Eur J Vasc Endovasc Surg; 1996 Aug; 12(2):151-61. PubMed ID: 8760976 [TBL] [Abstract][Full Text] [Related]